|
By Staff and Wire Reports
|
|
Monday, 21 September 2015 11:02 |
 Pluristem Therapeutics Inc. (PSTI.TA) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that Pluristem and the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), completed a successful meeting with the U.S. Food and Drug Administration (FDA) regarding the development program for PLX-R18 cells in the treatment of Acute Radiation Syndrome (ARS).
|
|
Read more...
|
|
By OTC Journal.com
|
|
Thursday, 17 September 2015 10:54 |
 If only Steve Jobs had access to this therapy before Pancreatic Cancer took his life. Had he known of PharmaCyte Biotech's (PMCB) live-cell encapsulation technology then, he may still be with us.
|
|
Read more...
|
|
By Staff and Wire Reports
|
|
Wednesday, 16 September 2015 12:39 |
 GlaxoSmithKline’s Breo Ellipta failed to meet its primary goal in a pivotal clinical trial of curbing death risk in patients suffering from chronic pulmonary obstructive disease.
|
|
Read more...
|
|
By FDAnews Drug Daily Bulletin
|
|
Tuesday, 15 September 2015 01:28 |
FDA enforcement of drug companies’ use of off-label promotion is being made more difficult by Amarin’s successful lawsuit against the agency and by a government website, ClinicalTrials.gov, a law professor says.
|
|
Read more...
|
|
By CRWE Press Release
|
|
Sunday, 13 September 2015 14:20 |
|
Orgenesis, Inc. (OTCQB:ORGS) and Scott Carmer the Company’s U.S. CEO, is featured in the Special Report: Curing Diabetes. To view the segment please visit:https://www.youtube.com/watch?v=6JhXF0VIj50.
|
|
Read more...
|
|
By Gail Dutton of The Life Sciences Report
|
|
Wednesday, 09 September 2015 22:03 |
 CAR T-cell therapies show amazing potential in treating blood cancers, but there's a lot of work to do before the cells are ready for commercialization. Alan Leong, senior analyst with BioWatch, tells The Life Sciences Report about the latest in CAR T-cell therapeutics and how some companies are hedging their bets by developing bispecific antibodies. He also describes the reality behind the growing excitement in regenerative medicine, and what investors should know about some very innovative, but often overlooked, small companies.
|
|
Read more...
|
|
By Josh Gee
|
|
Friday, 14 August 2015 18:20 |
 PDI, Inc. (NASDAQ:PDII) subsidiary Interpace Diagnostics has confirmed that ThyGenX Thyroid Oncogene Panel as well as ThyraMIR are under the ambit of largest independent Blue Cross Blue Shield plans which insures over 3.3 million lives.
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Wednesday, 05 August 2015 18:15 |
|
Regenerative medicine is just beginning to be understood by governments and investors alike. Last autumn, new regulations took effect in Japan that promise to speed patient access to some of these new therapies.
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Wednesday, 29 July 2015 17:13 |
|
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies developing stem cell and drug-device delivery systems that address complex disease indications ranging from blindness to spinal paralysis.
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Wednesday, 22 July 2015 15:22 |
 Investors who lament missing the U.S. biotech bull market might have another avenue to pursue. Biotech valuations in Australia are not in sync with U.S. biotech valuations, and comparable stocks from Down Under may have extraordinary technology platforms and huge upside potential. In this interview with The Life Sciences Report, Senior Healthcare Analyst John Hester of Bell Potter Securities discusses two hidden Australian biotech gems, one of which could ride the coattails of a U.S.-based product on a very positive regulatory path.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 5 of 56 |
